Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group Reply

被引：0
|
作者：
Montorsi, Francesco [1 ]
Moschini, Marco [1 ]
Briganti, Alberto [1 ]
机构：
[1] IRCCS Osped San Raffaele, Div Oncol, URI, Unit Urol, Milan, Italy
来源：
EUROPEAN UROLOGY ONCOLOGY | 2023年 / 6卷 / 03期
关键词：
D O I：
10.1016/j.euo.2023.03.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group
    Tan, Wei Shen
    Steinberg, Gary
    Witjes, J. Alfred
    Li, Roger
    Shariat, Shahrokh F.
    Roupret, Morgan
    Babjuk, Marko
    Bivalacqua, Trinity J.
    Psutka, Sarah P.
    Williams, Stephen B.
    Cookson, Michael S.
    Palou, Juan
    Kamat, Ashish M.
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (05): : 505 - 516
  • [2] BLADDER CANCER Defining intermediate-risk non-muscle-invasive bladder cancer
    Malkowicz, S. Bruce
    NATURE REVIEWS UROLOGY, 2014, 11 (08) : 430 - 432
  • [3] Defining intermediate-risk non-muscle-invasive bladder cancer
    S. Bruce Malkowicz
    Nature Reviews Urology, 2014, 11 : 430 - 432
  • [4] Treatment of intermediate-risk non-muscle-invasive bladder cancer (NMIBC)
    Hendricksen, Kees
    Witjes, J. Alfred
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (14) : 800 - 808
  • [5] Adjuvant therapy in intermediate-risk non-muscle-invasive bladder cancer
    Laukhtina, E.
    Moschini, M.
    Soria, F.
    Pradere, B.
    Yanagisawa, T.
    Kawada, T.
    Quhal, F.
    Von, Deimling M.
    Rajwa, P.
    Majdoub, M.
    Enikeev, D.
    Karakiewicz, P., I
    Robert, R. S.
    Babjuk, M.
    Shariat, S. F.
    EUROPEAN UROLOGY, 2023, 83
  • [6] Characterizing intermediate-risk non-muscle-invasive bladder cancer: Implications for the definition of intermediate risk and treatment strategy
    Matsumoto, Kazuhiro
    Kikuchi, Eiji
    Yanai, Yoshinori
    Hayakawa, Nozomi
    Ito, Yujiro
    Maeda, Takahiro
    Nagata, Hirohiko
    Miyajima, Akira
    Oya, Mototsugu
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (05) : 208 - 214
  • [7] Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer
    Laukhtina, Ekaterina
    Gontero, Paolo
    Babjuk, Marko
    Moschini, Marco
    Teoh, Jeremy Yuen-Chun
    Roupret, Morgan
    Trinh, Quoc-Dien
    Chlosta, Piotr
    Nyirady, Peter
    Abufaraj, Mohammad
    Soria, Francesco
    Klemm, Jakob
    Bekku, Kensuke
    Matsukawa, Akihiro
    Shariat, Shahrokh F.
    BJU INTERNATIONAL, 2024, 134 (04) : 644 - 651
  • [8] Significance of Bladder Neck Involvement in Risk Substratification of Intermediate-Risk Non-muscle-invasive Bladder Cancer
    Fukushima, Hiroshi
    Moriyama, Shingo
    Waseda, Yuma
    Fukuda, Shohei
    Uehara, Sho
    Tanaka, Hajime
    Kijima, Toshiki
    Yoshida, Soichiro
    Yokoyama, Minato
    Ishioka, Junichiro
    Matsuoka, Yoh
    Saito, Kazutaka
    Fujii, Yasuhisa
    EUROPEAN UROLOGY FOCUS, 2021, 7 (02): : 366 - 372
  • [9] The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer
    Chen, Jian-Xin
    Huang, Wen-Ting
    Zhang, Qing-Yun
    Deng, Cheng-En
    Wei, Jue-ling
    Xie, Yuan-Liang
    Lin, Rui
    Feng, Guan-Zheng
    Yang, Guang-Lin
    Long, Jun
    Lu, Hao-Yuan
    Mo, Zeng-nan
    BMC CANCER, 2023, 23 (01)
  • [10] The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer
    Jian-Xin Chen
    Wen-Ting Huang
    Qing-Yun Zhang
    Cheng-En Deng
    Jue-ling Wei
    Yuan-Liang Xie
    Rui Lin
    Guan-Zheng Feng
    Guang-Lin Yang
    Jun Long
    Hao-Yuan Lu
    Zeng-nan Mo
    BMC Cancer, 23 (1)
12345